VRDN logo

Viridian Therapeutics Inc. (VRDN)

$29.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VRDN

Market cap

$3.38B

EPS

-3.87

P/E ratio

--

Price to sales

29.72

Dividend yield

--

Beta

1.065646

Price on VRDN

Previous close

$30.87

Today's open

$30.69

Day's range

$29.75 - $31.37

52 week range

$13.18 - $34.29

Profile about VRDN

CEO

Stephen Mahoney

Employees

252

Headquarters

Waltham, MA

Exchange

NASDAQ Capital Market

Shares outstanding

113558449

Issue type

Common Stock

VRDN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on VRDN

Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing

Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.

news source

Benzinga • Nov 9, 2026

news preview

Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript

Viridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Thomas Smith - Leerink Partners LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Joseph Thome - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Dina Elmonshed - UBS Investment Bank, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Qiu Wu - Goldman Sachs Group, Inc., Research Division John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call.

news source

Seeking Alpha • Nov 9, 2026

news preview

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Based on these data, we believe VRDN-008 dosed subcutaneously every 8 weeks can deliver deep and sustain.

news source

Business Wire • Nov 9, 2026

news preview

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET. Conference Call and.

news source

Business Wire • Nov 6, 2026

news preview

Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead

Viridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market, but I see Lumvoa as well-positioned for continued growth, with more growth expected to come from elegrobart in late 2027. VRDN's near-term focus is on phase 1 data for VRDN-008 in the FcRn franchise, with expectations for deep IgG lowering and good safety and tolerability.

news source

Seeking Alpha • Nov 5, 2026

news preview

What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call

Viridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30.

news source

MarketBeat • Nov 4, 2026

news preview

Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript

Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026. "We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations," said Steve Mahoney, President and Chief Executive Offi.

news source

Business Wire • Nov 4, 2026

news preview

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $0.34 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Viridian Therapeutics Inc.

Open an M1 investment account to buy and sell Viridian Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VRDN on M1